Neurogene (Neurogene) Short-Term Capital Lease Obligation : $3.14 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Neurogene Short-Term Capital Lease Obligation?

Neurogene's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $3.14 Mil.

Neurogene's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 ($0.78 Mil) to Dec. 2023 ($2.88 Mil) and increased from Dec. 2023 ($2.88 Mil) to Mar. 2024 ($3.14 Mil).

Neurogene's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($0.61 Mil) to Dec. 2022 ($0.70 Mil) and increased from Dec. 2022 ($0.70 Mil) to Dec. 2023 ($2.88 Mil).

Neurogene Short-Term Capital Lease Obligation Historical Data

The historical data trend for Neurogene's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene Short-Term Capital Lease Obligation Chart

Neurogene Annual Data

Trend

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

0.61

0.70

2.88

Neurogene Quarterly Data
	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial			-	0.75	0.78	2.88	3.14

Neurogene Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Neurogene Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Neurogene's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurogene (Neurogene) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

535 W 24th Street, 5th Floor, New York, NY, USA, 10011

Website

https://www.neurogene.com

Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.

Neurogene (Neurogene) Headlines

From GuruFocus

Neurogene Announces Business Update and 2024 Outlook

By Business Wire • 01-05-2024

Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million

By Business Wire • 12-19-2023